To All UMass Worcester Faculty:
The UMass Center for Clinical and Translational Science (UMCCTS), in collaboration with Voyager Therapeutics, is announcing a special round of Pilot Project Programs (PPPs) focused on understanding and optimizing recombinant adeno-associated viral (rAAV) vectors for therapeutic use.
Investigators are invited to submit proposals related to the following topics:
Proposals will be evaluated by a Scientific Review Committee made up of representatives from UMass and Voyager in a two-step process:
Letter of Intent Due: Friday, December 12, 2014 by 5:00 pm (EST). Please send your Letter of Intent to: firstname.lastname@example.org
The Next Hundred Million Pilot Projects (NHMPP)serves as a dedicated pool of funding to spur innovative collaborations between MassBiologics of UMMS and investigators across the UMass System with the goal of enhancing the translation of discoveries for clinical use. Projects must include at least one investigator from MassBiologics of UMMS and a faculty investigator from at least one UMass campus.
Letter of Intent Due: Friday, October 31, 2014 by 5:00 pm (EST). Please send your Letter of Intent as a single PDF document to: email@example.com
To All UMass Worcester Faculty and Cubist Pharmaceutical Employees:
The UMCCTS, in collaboration with Cubist Pharmaceuticals, Inc., is announcing a special round of the Pilot Project Program (PPP) focused on understanding aspects of host-pathogen relationships that may lead to the development of novel measures to prevent or manage infectious diseases.
In this inaugural pilot program between UMCCTS and Cubist, a total of $350,000 is available to fund pilot projects (n = 2-4). Individual project awards of up to $120,000 over two years are allowed. Awards are expected to be made on a competitive basis by a scientific review committee to enable teams of joint investigators to accelerate the translation of innovative, cutting-edge research on host-pathogen interactions related to infectious diseases.
Applications are due: Friday, October 24, 2014 by 5:00 pm EST
Proposals should be submitted as a single PDF document to: Nathaniel.Hafer@umassmed.edu.
All UMass Worcester Researchers whose work meets the criteria are invited to apply:
CTI: An innovative Pfizer program that partners with leading academic medical centers and foundations nationwide to accelerate the translation of novel targets to the clinic. CTI's goal is to identify new compounds and accelerate research and drug development from validated target to proof-of-mechanism in the clinic. A partnership with CTI includes collaborative use of Pfizer's proprietary antibody drug discovery technologies and compound library, broad publishing rights and significant financial awards in the form of milestone and royalty payments for successful programs.
Pre-proposal Instructions - Please carefully review
Download the 3 attached forms:
Applications are due by: Friday, October 31, 2014 by 5:00 pm
Proposals should be submitted as a single PDF document to: Nathaniel.Hafer@umassmed.edu
Questions? Please contact Nate Hafer, PhD
This funding opportunity is designed to leverage the convening capacity of the UMCCTS to create new, multidisciplinary teams to address a pressing health need.
Applications (2 pages or less) are accepted on a rolling basis (no due date) to firstname.lastname@example.org. Investigators will be notified of award approximately 2-3 weeks post submission.
The intent of the UMCCTS Pilot Project Program (PPP) funding is to speed-up the rate of progress to move a research project, clinical finding, or other discovery into a broader network of activities, while maximizing the breadth of interdisciplinary skills applied to the research question. We are particularly interested in proposals which feature a clinical scientist working with a basic scientist and proposals with an emphasis on community-based research.
The next PPP solicitation is pending.
Training of investigators who will make a career of innovative, hypothesis-driven clinical and translational research is a top priority of the UMCCTS. The Clinical Research Scholar (K12) Program has been developed to address this need. The training program will combine coursework, seminars, and mentored research.
The next Clinical Research Scholar (K12) solicitation is pending.
The UMass LSMF supports projects that are inter-campus in orientation and directed towards life sciences projects related to clinical and translational research. To support this mission, projects must include at least one investigator from the UMass Worcester Campus and a collaborator from at least one of the other UMass campuses.
The next LSMF solicitation will be announced in 2015.
These awards focus on community engaged research, defined as “the process of working collaboratively with and through groups of people affiliated by geographic proximity, special interest, or similar situations to address issues affecting well-being of those people”.
The next Community Engagement solicitation is pending.